The human peroxisome proliferator-activated receptor gamma2 (PPARgamma2) Pro12Ala polymorphism is associated with decreased risk of diabetic nephropathy in patients with type 2 diabetes.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Diabetes

• Publication date

  2003-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2337/DIABETES.52.12.3010PMID 14633865
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Impact of two common polymorphisms in the PPARgamma gene on glucose tolerance and plasma insulin profiles in monozygotic and dizygotic twins: thrifty genotype, thrifty phenotype, or both?

  2003cited by this paper
• Testing for population subdivision and association in four case-control studies.

  2002cited by this paper
• Once and again-issues surrounding replication in genetic association studies.

  2002cited by this paper
• Peroxisome proliferator-activated receptor-gamma2 polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: The Berlin Diabetes Mellitus (BeDiaM) Study.

  2002influential reference
• Nephropathy in type 1 diabetes: a manifestation of insulin resistance and multiple genetic susceptibilities? Further evidence from the Pittsburgh Epidemiology of Diabetes Complication Study.

  2002cited by this paper
• The peroxisome proliferator-activated receptor-gamma2 Pro12A1a variant: association with type 2 diabetes and trait differences.

  2001cited by this paper
• The Pro12 -->Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes.

  2001influential reference
• The metabolic syndrome influences the risk of chronic complications in patients with Type II diabetes

  2001cited by this paper
• Prognostic factors in Brazilian diabetic patients starting dialysis: a 3.6-year follow-up study.

  2000cited by this paper
• The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient?

  2000cited by this paper
• The Pro12Ala Polymorphism in PPAR γ2 May Confer Resistance to Type 2 Diabetes

  2000cited by this paper
• The Pro12Ala polymorphism in PPAR gamma2 may confer resistance to type 2 diabetes.

  2000cited by this paper
• The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes.

  2000cited by this paper
• Freely associating

  1999cited by this paper
• Report of the expert committee on the diagnosis and classification of diabetes mellitus.

  1999cited by this paper
• The drama of the continuous increase in end-stage renal failure in patients with type II diabetes mellitus.

  1998cited by this paper
• A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity

  1998cited by this paper
• Non-operative management of patients with coronary artery disease: current indications for percutaneous coronary angioplasty.

  1998cited by this paper
• Molecular Scanning of the Human Peroxisome Proliferator Activated Receptor γ (hPPARγ) Gene in Diabetic Caucasians: Identification of a Pro12Ala PPARγ2 Missense Mutation

  1997cited by this paper
• Genetic Data Analysis II.

  1997cited by this paper
• The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure.

  1997cited by this paper
• The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (NIH Publication No. 98-4080)

  1997cited by this paper
• Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation.

  1997cited by this paper
• The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones.

  1996cited by this paper
• The structure - Activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones

  1996cited by this paper

• The impact of PPARγ and ApoE gene polymorphisms on susceptibility to diabetic kidney disease in type 2 diabetes mellitus: a meta-analysis

  2024cites this paper
• Molecular Dynamics Simulation and Essential Dynamics of Deleterious Proline 12 Alanine Single-Nucleotide Polymorphism in PPARγ2 Associated with Type 2 Diabetes, Cardiovascular Disease, and Nonalcoholic Fatty Liver Disease

  2022cites this paper
• Structure – Activity Relationship and Therapeutic Benefits of Flavonoids in the Management of Diabetes and Associated Disorders

  2021cites this paper
• Relationship of the Pro12Ala Polymorphism on the PPARy2 Gene With the Body Composition of Practitioners of Cyclic Exercises

  2021cites this paper
• PPARγ and Diabetes: Beyond the Genome and Towards Personalized Medicine

  2021cites this paper
• Association between Pro12Ala polymorphism and albuminuria in type 2 diabetic nephropathy

  2020cites this paper
• PPARG Pro12Ala Polymorphism with CKD in Asians: A Meta-Analysis Combined with a Case-Control Study—A Key for Reaching Null Association

  2020cites this paper
• Electronic Supplementary Material

  2019cites this paper
• The Pro12Ala polymorphism in the PPARγ2 gene is not associated with an increased risk of NAFLD in Iranian patients with type 2 diabetes mellitus

  2019cites this paper
• Role of TCF7L2 and PPARG2 Gene Polymorphisms in Renal and Cardiovascular Complications among Patients with Type 2 Diabetes: A Cohort Study

  2019cites this paper
• PPARG genotypes are not a major modifiers of chronic kidney disease progression among the diabetic nephropathy patients

  2018cites this paper
• Association between PPARG Pro 12 Ala polymorphism and diabetic nephropathy risk ; an updated meta-analysis of 27 studies

  2018cites this paper
• The Single Nucleotide Polymorphism PPARG2 Pro12Ala Affects Body Mass Index, Fat Mass, and Blood Pressure in Severely Obese Patients

  2018cites this paper
• EVALUATION OF Β-LACTAM AND AMINOGLYCOSIDES SYNERGISTIC EFFECT ON MULTIDRUG RESISTANT PSEUDOMONAS

  2017cites this paper
• RETRACTED: Association between peroxisome proliferator-activated receptor, UCP3 and lipoprotein lipase gene polymorphisms and obesity in Chinese adolescents.

  2017cites this paper
• Association analysis of PPARγ (p.Pro12Ala) polymorphism with type 2 diabetic retinopathy in patients from north India

  2017cites this paper
• Insulin receptor gene polymorphisms modify the progression of kidney failure in diabetic nephropathy patients

  2017cites this paper
• The C161T Polymorphism in Peroxisome Proliferator-Activated Receptor ɣ2, but Not Pro12Ala, Is Associated with Diabetic Retinopathy in Type 2 Diabetes Mellitus in an Egyptian Population

  2016cites this paper
• Role of PPARG (Pro12Ala) in Malaysian type 2 diabetes mellitus patients

  2016cites this paper
• Identifying Common Genetic Risk Factors of Diabetic Neuropathies

  2015cites this paper
• The PPARγ2 Pro12Ala variant is protective against progression of nephropathy in people with type 2 diabetes

  2015cites this paper
• Peroxisome proliferator-activated receptor γ Pro 12 Ala polymorphism decrease the risk of diabetic nephropathy in type 2 diabetes : a meta analysis

  2015cites this paper
• Genetics of cardiovascular and renal complications in diabetes

  2015cites this paper
• Peroxisome proliferator-activated receptor γ Pro12Ala polymorphism decrease the risk of diabetic nephropathy in type 2 diabetes: a meta analysis.

  2015cites this paper
• Diabetic Nephropathy without Diabetes

  2015cites this paper
• Screening, Early Diagnosis, Genetic Markers, and Predictors of Diabetic Nephropathy

  2014cites this paper
• Peroxisome proliferator activated receptor γ2 gene Pro12Ala gene polymorphism in type 2 diabetes and its relationship with diabetic nephropathy.

  2014cites this paper
• Association of peroxisome proliferator-activated receptor γ Pro12Ala gene polymorphism with type 2 diabetic nephropathy risk in Caucasian population

  2014cites this paper
• The Rate of Decline of Glomerular Filtration Rate May Not Be Associated with Polymorphism of the PPARγ2 Gene in Patients with Type 1 Diabetes and Nephropathy

  2014cites this paper
• The association between lipid metabolism gene polymorphisms and nephropathy in type 2 diabetes: a meta-analysis

  2014cites this paper
• Evaluation of the antinociceptive properties of Hyptis crenata Pohl (Brazilian mint)

  2013influential citation
• The association between the PPARγ2 Pro12Ala polymorphism and nephropathy susceptibility in type 2 diabetes: a meta-analysis based on 9,176 subjects

  2013influential citation
• Association of Pro12Ala polymorphism in peroxisome proliferator activated receptor gamma with proliferative diabetic retinopathy

  2013cites this paper
• Role of the ACE ID and PPARG P12A Polymorphisms in Genetic Susceptibility of Diabetic Nephropathy in a South Indian Population

  2013cites this paper
• Role of insulin resistance in kidney dysfunction: insights into the mechanism and epidemiological evidence.

  2013cites this paper
• Association between PRO12ALA polymorphism of the PPAR-γ2 gene and type 2 diabetes mellitus in Iranian patients

  2013cites this paper
• The association between diabetic nephropathy and polymorphisms in PPARγ Pro 12Ala and CCR5δ 32 genes in type 2 diabetes

  2013cites this paper
• Biomarkers of diabetic nephropathy, the present and the future.

  2012cites this paper
• Meta-analysis of association between the Pro12Ala polymorphism of the peroxisome proliferator–activated receptor-γ2 gene and diabetic retinopathy in Caucasians and Asians

  2012cites this paper
• Association Between the PPARG Gene Polymorphism and the Risk of Diabetic Nephropathy: A Meta-Analysis

  2012cites this paper
• Genetic Basis of Diabetic Nephropathy 697 RATIONALE FOR GENE DISCOVERY IN DIABETIC KIDNEY DISEASE

  2012cites this paper
• Harnessing the potential clinical use of medicinal plants as anti-diabetic agents

  2012cites this paper
• Genetic and environmental factors associated with type 2 diabetes and diabetic vascular complications.

  2012cites this paper
• Effects of peroxisome proliferator activated receptor-gamma 2 gene Pro12Ala polymorphism on fasting blood lipids: a meta-analysis.

  2011cites this paper
• Diabetic nephropathy : pathology, genetics and carnosine metabolism

  2011cites this paper
• PPARγ2 P12A polymorphism and albuminuria in patients with type 2 diabetes: a meta-analysis of case-control studies.

  2011influential citation
• Pro12Ala Polymorphism in the PPARG Gene Contributes to the Development of Diabetic Nephropathy in Chinese Type 2 Diabetic Patients

  2010cites this paper
• Nefropatía por diabetes mellitus tipo 2: un rasgo multifactorial con umbral y su mapa mórbido cromosómico

  2010cites this paper
• The Genetic Background Difference Between Diabetic Patients with and without Nephropathy in a Taiwanese Population by Linkage Disequilibrium Mapping Using 382 Autosomal STR Markers

  2010cites this paper
• Genetics of diabetic nephropathy Bases genéticas da nefropatia diabética

  2010cites this paper
• Pro12Ala Polymorphism in the PPARG Gene Contributes to the Development of Diabetic Nephropathy in Chinese Type 2 Diabetic Patients

  2010cites this paper
• Genetics of diabetic nephropathy.

  2010cites this paper
• Peroxisome Proliferator–Activated Receptor γ Polymorphism Pro12Ala Is Associated With Nephropathy in Type 2 Diabetes

  2010cites this paper
• GENETICS ASPECTS OF DIABETIC NEPHROPATHY

  2010cites this paper
• Genética da predisposição à nefropatia diabética em pacientes com diabetes melito tipo 2

  2010cites this paper
• Association and interaction analyses of genetic variants in ADIPOQ, ENPP1, GHSR, PPARgamma and TCF7L2 genes for diabetic nephropathy in a Taiwanese population with type 2 diabetes.

  2009cites this paper
• Papel dos lipídeos da dieta na nefropatia diabética Role of dietary lipids in diabetic nephropathy

  2009cites this paper
• PPARγ2Pro12Ala Polymorphism and Human Health

  2009cites this paper
• [Role of dietary lipids in diabetic nephropathy].

  2009cites this paper
• Pathogenesis and Pathophysiology of Diabetic Nephropathy

  2009cites this paper
• Pro 12 Ala polymorphism in the PPARG gene contributes to the development of diabetic nephropathy in Chinese type 2 diabetes

  2009influential citation
• Pro12Ala Polymorphism in the PPARG Gene Contributes to the Development of Diabetic Nephropathy in Chinese Type 2 Diabetic Patients

  2009cites this paper
• Role Of Peroxisome Proliferator- Activated Receptor Gamma2(Ppar-γG2) Gene Polymorphism In Type 2 Diabetes Mellitus

  2009cites this paper
• Genetic Variation of PPARs

  2009cites this paper
• Impact of the PPAR-γ2 Pro12Ala Polymorphism and ACE Inhibitor Therapy on New-Onset Microalbuminuria in Type 2 Diabetes: Evidence From BENEDICT

  2009cites this paper
• Susceptibilidade genética e outros fatores de risco associados ao sobrepeso e à obesidade em populações afro-descendentes do Vale do Ribeira-SP

  2008cites this paper
• Alanine variant of the Pro12Ala polymorphism of the PPARgamma gene might be associated with decreased risk of diabetic retinopathy in type 2 diabetes.

  2008cites this paper
• Characterization of a Novel Polymorphism in PPARG Regulatory Region Associated with Type 2 Diabetes and Diabetic Retinopathy in Italy

  2008cites this paper
• Association Study of the Peroxisome Proliferators-Activated Receptor γ2 Pro12Ala Polymorphism with Diabetic Nephropathy

  2008cites this paper
• The PPAR gamma 2 Pro12Ala variant predicts ESRD and mortality in patients with type 1 diabetes and diabetic nephropathy.

  2008cites this paper
• Candidate Genes for Late Diabetic Complications

  2007cites this paper
• Peroxisome proliferator-activated receptor gamma polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes.

  2007cites this paper
• Association of the peroxisome proliferator-activated receptor-γ2 Pro12Ala but not the C1431T gene variants with lower body mass index in Type 2 diabetes

  2007cites this paper
• Effects of a PPARG gene variant on obesity characteristics in Brazil.

  2007cites this paper
• Gene and protein markers of diabetic nephropathy.

  2007cites this paper
• Peroxisome proliferator-activated receptor γ polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes

  2007cites this paper
• Lack of association between the Pro12Ala polymorphism in PPAR-gamma2 gene and body weight changes, insulin resistance and chronic diabetic complications in obese patients with type 2 diabetes.

  2006cites this paper
• Peroxisome proliferator-activated receptor-γ2 Pro12Ala polymorphism is associated with reduced risk for ischemic stroke with type 2 diabetes

  2006cites this paper
• Lack of Association between the Pro12Ala Polymorphism in PPAR-γ2 Gene and Body Weight Changes, Insulin Resistance and Chronic Diabetic Complications in Obese Patients with Type 2 Diabetes

  2006cites this paper
• Peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism is associated with reduced risk for ischemic stroke with type 2 diabetes.

  2006cites this paper
• Assessment of 115 candidate genes for diabetic nephropathy by transmission/disequilibrium test.

  2005cites this paper
• Haplotype analysis of NAD(P)H oxidase p22 phox polymorphisms in end-stage renal disease

  2005cites this paper
• Peroxisome Proliferator Activated Receptors

  2005cites this paper
• Drug Insight: thiazolidinediones and diabetic nephropathy—relevance to renoprotection

  2005cites this paper
• The peroxisome proliferator activated receptorgamma2 (PPARgamma2) Pro12Ala variant: lack of association with type 2 diabetes in obese and non obese Tunisian patients.

  2005cites this paper
• Peroxisome proliferator-activated receptor-gamma2 Pro12Ala and endothelial nitric oxide synthase-4a/b gene polymorphisms are not associated with hypertension in diabetes mellitus type 2.

  2005cites this paper
• The peroxisome proliferator activated receptorφ2 (PPARφ2) Pro12Ala variant: lack of association with type 2 diabetes in obese and non obese Tunisian patients

  2005cites this paper
• Peroxisome proliferator-activated receptor-γ2 Pro12Ala and endothelial nitric oxide synthase-4a/b gene polymorphisms are not associated with hypertension in diabetes mellitus type 2

  2005cites this paper
• Gly482Ser polymorphism of the peroxisome proliferator–activated receptor‐γ coactivator‐1 gene might be a risk factor for diabetic retinopathy in Slovene population (Caucasians) with type 2 diabetes and the Pro12Ala polymorphism of the PPARγ gene is not

  2005cites this paper
• The human obesity gene map: the 2004 update.

  2005cites this paper
• Association between Pro12Ala polymorphism of the PPAR‐γ2 gene and insulin sensitivity in Brazilian patients with type‐2 diabetes mellitus

  2005cites this paper
• Genetics and molecular biology.

  2005cites this paper
• Impact of genetic variation of PPARgamma in humans.

  2004cites this paper
• Gene expression profiles of peripheral blood cells in type 2 diabetes and nephropathy in Asian Indians

  2004cites this paper
• Impact of genetic variation of PPARγ in humans

  2004cites this paper
• Lack of evidence for the 1484 insG variant at the 3 0-UTR of the protein tyrosine phosphatase 1 B ( PTP 1 B ) gene as a genetic determinant of diabetic nephropathy development in type 1 diabetic patients

  2004cites this paper
• Phenotypic consequences of the peroxisome proliferator-activated receptor-gamma Pro12Ala polymorphism: the weight of the evidence in genetic association studies.

  2004cites this paper
• Lack of evidence for the 1484insG variant at the 3'-UTR of the protein tyrosine phosphatase 1B (PTP1B) gene as a genetic determinant of diabetic nephropathy development in type 1 diabetic patients.

  2004cites this paper
• Renal involvement in Cogan’s syndrome

  2004cites this paper
• Adiponectin gene polymorphism (G276T) is not associated with incipient diabetic nephropathy in Japanese type 2 diabetic patients.

  2004cites this paper